Role of CD24 and CD24hi Neutrophils in key co-morbidities associated with the MyeloProliferative Neoplasmscore
NeutroMPN · Horizon Europe grant · 2026-06-01–2028-05-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-MSCA-2025-PF · scheme HORIZON-TMA-MSCA-PF-EF · topic HORIZON-MSCA-2025-PF-01-01. CORDIS record →
Objective
Neutrophils are the most abundant leukocytes in the organism and represent the first line of immune defence against pathogens. Recent discoveries highlighted a new pro-tumoral subset of neutrophils implicated in the emergence of solid cancer. Yet, the role of this subset of neutrophils in the context of hematological clonal disorders, such as myeloproliferative neoplasms (MPNs), remains under investigated.MPNs are then characterized by reduced life quality and associated complications: thrombosis, bone marrow scarring impeding normal hematopoiesis (myelofibrosis) and leukemic transformation. These hematological diseases have a major social cost, that will be amplified in the next years with the aging population. Main therapies for MPNs are focused on symptoms and new treatments are needed. We recently discovered that neutrophils produced by MPN cancerous cells in the bone marrow (BM) are characterized by high expression of CD24 (CD24hi) and are involved in the development of myelofibrosis (BM scarring) in MPNs. However, the possible role of CD24 or these inflammatory neutrophils in key co-morbidities in MPN, such as thrombosis (blood clotting) and leukemic transformation, are unknown. This proposal aims at filling this critical gap of knowledge through three independent, yet highly interconnected, work packages: 1) validation of CD24 as functional biomarker for prognosis and novel personalized treatment; 2) role of CD24hi neutrophils in MPN thrombosis risk and 3) impact of CD24hi neutrophils on leukemic transformation. NeutroMPN project merges the expertise of the applicant in hematopoietic mechanisms of leukemic transformation in human and humanised models of MPN with the host group’s knowledge and resources in the microenvironment in MPN and leukemia. A 3-month secondment will provide necessary training in animal models of MPN thrombosis. Together, this project will test a new functional biomarker for prognosis and personalized treatment in MPN.
Beneficiaries (2)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| UNIVERSIDAD DE SEVILLA | ES | coordinator | €209,915 | |
| UNIVERSITE DE BORDEAUX | FR | associatedPartner | — |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.